Ritzmann Dorin
FMH Gynecology and Obstetrics, Medizin Feminin Private Practice, Dietikon, Switzerland.
Complement Med Res. 2024;31(2):124-132. doi: 10.1159/000536193. Epub 2024 Jan 11.
Urogenital atrophy and its sequelae, particularly genital dryness, urological problems, and pain on genital touching, are common medical problems for menopausal women and women undergoing antihormonal cancer treatment. To meet the requirements for a nonhormonal local treatment, a compounded herbal preparation was developed as a vaginal ovule (Dioscorea comp. ovulum), and the efficacy and applicability of this herbal treatment were investigated.
This was a retrospective chart review of patients' records. The study was approved by the Ethics Committee of the Canton of Zurich (project number BASEC 2016-01982). Between 2007 and 2011, patients with urogenital atrophy and related symptoms, who wanted to initiate herbal treatment, were asked for consent to be interviewed (4-point rating scale) and examined gynecologically with photo documentation of their vaginal discharge. A total of 26 patients met the enrollment criteria and consented to the procedure. The first 8 weeks consisted of a daily application of low-dose Dioscorea comp. ovulum followed by high-dose Dioscorea comp. ovule twice weekly for at least 3 months.
A total of 23 patients completed the trial. Of the 19 patients in the subgroup with an atrophic vaginal maturation index (VMI), 16 achieved a eutrophic VMI. Four patients began therapy with hypotrophy. There was a 96% decrease in complaints (22/23). The genital dryness score decreased from 1.80 to 0.25 points, urological problems from 2.38 to 0.85 points, and pain on genital touching from 1.70 to 0.60 points. Application, tolerability, and medical safety of the formula were good.
The phytotherapeutic compounded preparation Dioscorea comp. ovule (Dioscorea villosa, Glycine max, Salvia officinalis) is suitable for the treatment of urogenital atrophy and its sequelae.
泌尿生殖系统萎缩及其后遗症,尤其是生殖器干燥、泌尿系统问题以及生殖器接触疼痛,是绝经后女性和接受抗激素癌症治疗的女性常见的医学问题。为满足非激素局部治疗的需求,研发了一种复方草药制剂作为阴道栓剂(薯蓣复方栓剂),并对这种草药治疗的疗效和适用性进行了研究。
这是一项对患者记录的回顾性图表审查。该研究得到了苏黎世州伦理委员会的批准(项目编号BASEC 2016 - 01982)。在2007年至2011年期间,对有泌尿生殖系统萎缩及相关症状且希望开始草药治疗的患者,请求其同意接受访谈(4分制评分量表)并进行妇科检查,同时对其阴道分泌物进行照片记录。共有26名患者符合纳入标准并同意该程序。最初8周每天应用低剂量薯蓣复方栓剂,随后每周两次应用高剂量薯蓣复方栓剂,持续至少3个月。
共有23名患者完成试验。在阴道成熟指数(VMI)呈萎缩性的亚组中的19名患者中,16名实现了阴道上皮的富营养化。4名患者开始治疗时存在萎缩。症状减少了96%(22/23)。生殖器干燥评分从1.80降至0.25分,泌尿系统问题从2.38降至0.85分,生殖器接触疼痛从1.70降至0.60分。该配方的应用、耐受性和医疗安全性良好。
植物治疗复方制剂薯蓣复方栓剂(薯蓣、大豆、丹参)适用于治疗泌尿生殖系统萎缩及其后遗症。
<标题>背景</标题>泌尿生殖系统萎缩及其后果,特别是生殖器干燥、泌尿系统问题和生殖器接触疼痛,是绝经后女性和接受抗激素癌症治疗的女性常见的医学问题。为满足非激素局部治疗的需求,开发了一种植物制剂,制成阴道栓剂(薯蓣复方栓剂)。研究了这种植物治疗的有效性和适用性。<标题>患者和方法</标题>这是一项回顾性分析。研究方案得到了苏黎世州伦理委员会的批准(项目编号BASEC 2016 - 01982)。在2007年至2011年期间,对有泌尿生殖系统萎缩及相关症状且希望开始植物治疗的合适患者,请求其同意接受访谈(4分制评分)并进行妇科检查,同时对阴道分泌物进行照片记录(天然制剂)。26名患者符合标准并同意该程序。<标题>治疗</标题>在每天应用低剂量薯蓣复方栓剂后,每周两次应用高剂量薯蓣复方栓剂,持续至少3个月。<标题>结果</标题>共有23名患者完成研究。在阴道成熟指数(VMI)呈萎缩性的亚组中的19名患者中,16名达到了富营养化的阴道上皮。4名患者开始治疗时存在萎缩。96%(22/23)的患者症状有所减轻:生殖器区域干燥从1.80分降至0.25分,泌尿系统问题从2.38分降至0.85分,生殖器接触疼痛从1.70分降至0.60分。该复方制剂的应用、耐受性和医疗安全性良好。<标题>结论</标题>植物治疗复方制剂薯蓣复方栓剂(绒毛薯蓣、大豆、丹参)适用于治疗泌尿生殖系统萎缩及其后果。